The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis

Yi-Ying Wu1,2*, Tzu-Chuan Huang1*, Tsung-Neng Tsai2,3, Jia-Hong Chen1,4, Ming-Shen Dai1, Ping-Ying Chang1, Ching-Liang Ho1, Ren-Hua Ye1, Tsai-Rong Chung5, Yeu-Chin Chen1, Tsu-Yi Chao2,4,6*

1 Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China, 2 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei City, Taiwan, Republic of China, 3 Division of Cardiology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China, 4 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan, Republic of China, 5 National Institute of Cancer Research, Miaoli County, Taiwan, Republic of China, 6 Division of Hematology and Oncology, Department of Medicine, Taipei Medical University, Shuang-Ho Hospital, New Taipei City, Taiwan, Republic of China

* These authors contributed equally to this work.

10575@s.tmu.edu.tw

Abstract

Objective

Trastuzumab-containing treatment regimens have been shown to improve survival outcomes in HER2-positive breast cancer (BC). It is much easier to infuse a fixed one-vial dose to every patient on a regular schedule in the general clinical setting. The aims of this study were evaluating the efficacy of a 440 mg fixed-dose of trastuzumab administered on a monthly infusion schedule, and the risk factors for cardiac events.

Patients and methods

We retrospectively reviewed data from 300 HER2-positive BC patients in our institute: 208 were early-stage BC patients undergoing adjuvant trastuzumab treatment, and 92 were metastatic BC patients treated with trastuzumab infusions until disease progression. There were 181 patients receiving regular trastuzumab infusions every 3 weeks (Q3W; 8 mg/kg loading dose followed by 6 mg/kg every 3 weeks), and the other 119 patients were treated monthly with a fixed 440 mg dose (QM; fixed 440 mg every 4 weeks).

Results

The medians of progression-free survival (PFS) and overall survival (OS) in the adjuvant setting were not reached in both treatment groups. In the metastatic setting, there was no significant difference between groups in PFS or OS. The median time to significant cardiovascular (CV) dysfunction was 4.54 months. The incidence of congestive heart failure requiring medication in our cohort was 3.4%.
Conclusion
In our study, we found that fixed-dose monthly trastuzumab was feasible and effective. In addition, the CV risk was not higher with the fixed-dose protocol. This treatment modality could lower the cost and was easier to implement in clinical practice. Larger prospective randomized studies with longer-term follow up are needed to confirm our results.

Introduction
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the HER2 transmembrane growth factor receptor [1]. Around 20% to 30% of all invasive breast carcinomas are HER2-positive, and most of these have aggressive clinical behavior along with a poor outcome [2]. Several clinical trials have already shown that treating HER2-overexpressing metastatic breast cancer (BC) with trastuzumab, either alone or in combination with chemotherapy, significantly improves time to progression, duration of response, and survival [3, 4]. Trastuzumab has also been shown to be an effective adjuvant therapy for HER2-positive early-stage BC patients [5, 6].

The most common side effect of trastuzumab is cardiomyopathy, reported to affect around 2.8% to 3.3% of patients [7]. Most clinical trials monitor heart function via resting left ventricular ejection fraction (LVEF), and the incidence of trastuzumab discontinuation due to cardiac events is low [8]. Some researchers have found that previous treatment with anthracycline regimens, menopause status, radiotherapy, and the frequency of trastuzumab infusion might be associated with a higher incidence of cardiomyopathy [9]. The cardiotoxicity appears to be reversible, and left ventricular dysfunction often normalizes after withdrawal of trastuzumab [10].

Each clinical trial has used a different dosage and infusion frequency of trastuzumab. The most common dosage was 4 mg/kg for the loading dose followed by 2 mg/kg per week [6]. In the HERceptin Adjuvant (HERA) trial [11], the dosage was adjusted to 8 mg/kg for the loading dose followed by 6 mg/kg every 3 week for the clinical convenience. However, Pearson et al. reported 24% of trastuzumab dispensed was discarded, at a cost of $21.1 million Australian [12]. It is important and required immediate attention to minimize drug wastage. In Taiwan, one vial of Herceptin contains 440 mg. The waste of expensive trastuzumab can be occurred and also becomes a pharmacoeconomic stress when a patient receives a weight-based infusion weekly or triweekly protocol. Therefore, some BC patients receive fixed-dose monthly trastuzumab of 440mg in order to reduce the frequency of drug administration and even to lower their financial stress. However, the efficacy of this real-world practice is not known yet.

In this retrospective study, we try to analyze the outcomes of patients with early-stage and metastatic BC treated with either a fixed-dose (440 mg trastuzumab given as a monthly infusion) or with a weight-based infusion triweekly protocol. We studied the efficacy of the fixed-dose monthly trastuzumab dose in our cohort by measuring the time to progression and overall survival in our study cohort. We also evaluated possible risk factors for cardiotoxicity.

Materials and Methods
Study population
We retrospectively collected data from HER2-positive BC patients treated with trastuzumab at Tri-Service General Hospital from September 2006 to December 2014. Those treated with
trastuzumab containing dual blockade, enrolled in clinical trials, or unfit for treatment were excluded. The primary objective of this study was to evaluate the efficacy of a 440 mg fixed-dose of trastuzumab on a monthly infusion schedule (QM group) compared to a triweekly weight based dose protocol (Q3W group) in adjuvant and metastatic setting. The secondary aim was to evaluate risk factors for cardiac events in our cohort.

Each patient completed staging workup including chest radiography, abdominal ultrasonography, and a bone scan. Advanced-stage individuals were examined by positron emission tomography and brain magnetic resonance imaging. The patients’ clinical information and laboratory data were collected and analyzed from medical records. Pathological slides were examined. The expression of estrogen receptor (ER) was determined by immunohistochemical (IHC) staining of paraffin-embedded tumor. HER2 overexpression was defined as an IHC score of 3+ (Dako) or amplification by fluorescence in situ hybridization. All of these studies were performed in accordance with the guidelines of the Helsinki Declaration and were approved by the Human Subjects Protection Offices (IRB) of Tri-Service General Hospital.

Treatment and follow-up modalities

Patients were treated as clinically indicated, and therefore trastuzumab was often combined with chemotherapy. In early-stage BC, the Q3W group received adjuvant trastuzumab treatment with a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for up to 1 year. In the QM group, trastuzumab was administered as a fixed 440 mg monthly dose for 12 months as adjuvant therapy. In metastatic BC, monthly or triweekly trastuzumab was administered until disease progression.

Cardiac function evaluation

Echocardiography was performed before treatment and every 3–6 months, as clinically applicable. LVEFs were measured and recorded. Trastuzumab-related cardiotoxicity was classified into five grades as defined in the previous literature [6]:

- Grade I: asymptomatic decline in LVEF of >10% from baseline evaluation.
- Grade II: asymptomatic decrease in LVEF of <50% or ≥20% compared to the baseline value.
- Grade III: heart failure responsive to treatment.
- Grade IV: severe or refractory heart failure, or heart failure requiring intensive medical therapy and/or intubation.
- Grade V: death related to cardiac toxicity.

Treatment with a trastuzumab-containing regimen was discontinued or a trastuzumab rechallenge was considered by the clinical oncologist if the patient had cardiotoxicity of more than grade II severity.

Statistical analyses

All analyses were performed using SPSS version 18.0 software for Windows (SPSS, Inc.). The significance level was 5% for all analyses. All descriptive data are expressed as the median ± standard deviation. Two-tailed t tests and chi-square tests were used to compare the baseline characteristics of the Q3W and QM groups. Log-rank tests and Kaplan-Meier plots were used to analyze each groups’ progression free survival (PFS), overall survival (OS), and time to cardiac events. Cox-regression models were used to evaluate multiple variables. The risk factors for cardiac events were analyzed with the chi-square test.
Results

Patient characteristics

Two hundred and eight patients with early-stage HER2-positive BC and 92 patients with HER2-positive metastatic BC were treated with a trastuzumab-containing regimen. The demographic differences between the Q3W and QM groups were compared and are shown in Table 1. All patients were women with a median age of 52 years. The patients in the QM group were slightly younger ($p=0.021$). The lesion side, radiotherapy plan, and ER positivity rate were similar in the two groups. However, in the adjuvant setting, the Q3W group had a higher proportion of patients with stage IIIA to IIIC disease and a higher proportion of patients who received a chemotherapy regimen containing anthracycline plus taxane than the QM group ($31.1\%$ versus $18.6\%$ and $59.7\%$ versus $38.7\%$, respectively). In the adjuvant setting, the total treatment cycles of trastuzumab were 18 for the Q3W group, and 12 for the QM group. The average dosage of trastuzumab for each cycle was 360 mg in the Q3W group. On the other side, the median treatment cycles were the same in both groups (15 cycles) in the metastatic setting. The average dosage of trastuzumab for each cycle was 336 mg in the Q3W group. There were very few patients who had cardiovascular (CV) risk factors. We used age ($>55$ years-old), hypertension, diabetes, hyperlipidemia, and smoking to define a total CV risk group. We found that the Q3W and QM groups had relatively similar CV risks ($p=0.44$).

Table 1. The clinical demographic differences between both study groups.

| Variables           | Q3W       | QM       | $p$ value |
|---------------------|-----------|----------|-----------|
| Patient number      | N = 181   | N = 119  |           |
| Age (years±SD)      | 53.2 ±10.4 | 50.3 ±10.6 | 0.021     |
| Side (%)            | Right     | Left     | Bilateral |           |
|                     | 89 (49.2) | 88 (48.6) | 4 (2.2)   |           |
|                     | 48 (40.3) | 66 (55.5) | 5 (4.2)   |           |
| Stage (%)           | Stage I   | Stage II | Stage IIIB |          |
|                     | 32 (17.7) | 37 (20.4) | 26 (14.4) |           |
|                     | 25 (21.0) | 23 (19.3) | 9 (7.6)   |           |
|                     | 19 (10.5) | 8 (4.4)   | 16 (8.8)  |           |
|                     | 6 (5.0)   | 4 (3.4)   | 3 (2.5)   |           |
|                     | 43 (23.8) | 32 (17.7) | 32 (17.7) | 0.735     |
|                     | 49 (41.2) | 23 (19.3) | 23 (19.3) |           |
| Hypertension (%)    | 17 (9.4)  | 11 (6.1)  | 11 (6.1)  | 0.282     |
| Diabetes (%)        | 8 (10.5)  | 10 (11.9) | 10 (11.9) |           |
| Smoking (%)         | 6 (3.3)   | 3 (2.5)   | 3 (2.5)   | 0.681     |
| Hyperlipidemia (%)  | 96 (53.0) | 52 (43.7) | 52 (43.7) | 0.171     |
| ERa (%)             | 114 (63.0)| 64 (58.2) | 64 (58.2) | 0.274     |
| Radiotherapy (%)    | 19 (10.5) | 10 (5.5)  | 10 (5.5)  |           |
| Chemotherapy (%)    | 41 (22.7) | 13 (10.9) | 13 (10.9) | <0.0001   |
| Taxaneb             | 6 (3.3)   | 10 (8.4)  | 10 (8.4)  |           |
| Epirubicin          | 7 (3.9)   | 39 (32.8) | 39 (32.8) |           |
| Doxorubicin         | 40 (22.1) | 12 (10.1) | 12 (10.1) |           |
| Epirubicin + Taxane | 68 (37.6) | 34 (28.6) | 34 (28.6) |           |

a. ER: estrogen receptor
b. Taxane included docetaxel or paclitaxel

doi:10.1371/journal.pone.0151112.t001
Time to progression and overall survival

The survival of the metastatic cohort was evaluated with the log-rank test and Kaplan-Meier plots. No significant difference in PFS and OS was noted between the Q3M and QM groups (Fig 1A and 1B; \( p = 0.23 \) and \( p = 0.19 \), respectively). We used a Cox-regression model to try to identify possible confounding factors such as age, ER positivity, lymphovascular invasion, and tumor grade. No specific factors were found to influence PFS or OS in the metastatic cohort (data not shown). The medians of both PFS and OS in the adjuvant group were not reached by the end of the study (Fig 1C and 1D; \( p = 0.30 \) and \( p = 0.61 \), respectively). However, through analysis with a Cox-regression model, we found that in the adjuvant cohort, the QM group with younger ages had slightly better PFS than the Q3W group (hazard ratio = 2.445, 95% confidence interval = 1.021–5.858, \( p = 0.045 \)).

CV events

A total of 261 patients were enrolled to analyze the CV risk factors using the Chi-square test for variables such as trastuzumab infusion frequency, previous anthracycline–containing regimens, lesion side, radiotherapy plan, and CV risk factors. Thirty-nine patients were excluded
due to irregular echocardiographic evaluation and a lack of medical information about CV risk factors. We found that no factors other than age correlated to cardiac toxicity (Table 2, \( p = 0.032 \)). The incidence of asymptomatic LVEF declined was 10.7%, and there was no significant difference between both groups (\( p = 0.693 \)). Excluding those with asymptomatic patients, the incidence of congestive heart failure (CHF) (>grade II toxicity) in our patients was 3.4%. Six of these patients were in the Q3W group, and three were in the QM group. No cardiac death (grade V toxicity) occurred in our study population.

The median time to significant CV dysfunction (>grade II toxicity) was 4.54 months, as calculated using a Kaplan-Meier plot (Fig 2A); there was no difference between the Q3W and QM groups (Fig 2B, \( p = 0.71 \)). The median duration until LVEF recovery to more than 50% was 9.5 months. However, four patients (30.8%) still suffered from symptomatic CHF despite medical

### Table 2. The evaluation of trastuzumab-related cardiotoxicity by variable factors.

| Variables          | \( \Delta \text{EF} \) 10–20% \( (n\%) \) | \( \Delta \text{EF} \) >20% or EF <50% \( (n\%) \) | CHF need medication \( (n\%) \) | CHF need ICU or intubation \( (n\%) \) | \( P \) value |
|--------------------|------------------------------------------|------------------------------------------|-------------------|------------------------------------------|--------------|
| Trastuzumab        |                                          |                                          |                   |                                          | 0.913        |
| Q3W                | 13(8.2)                                  | 2(1.3)                                  | 3(1.9)            | 3(1.9)                                  |              |
| QM                 | 11(10.7)                                 | 2(1.9)                                  | 2(1.9)            | 1(1.0)                                  |              |
| Chemotherapy       |                                          |                                          |                   |                                          | 0.943        |
| Other              | 2(7.7)                                   | 0(0)                                    | 1(3.8)            | 0(0)                                    |              |
| Taxane*            | 2(4.4)                                   | 1(2.2)                                  | 0(0)              | 0(0)                                    |              |
| Epirubicin         | 1(6.7)                                   | 0(0)                                    | 0(0)              | 0(0)                                    |              |
| Doxorubicin        | 6(14.6)                                  | 1(2.4)                                  | 1(2.4)            | 1(2.4)                                  |              |
| Epirubicin + Taxane| 3(7.0)                                   | 1(2.3)                                  | 1(2.3)            | 0(0)                                    |              |
| Doxorubicin + Taxane| 10(11.0)                               | 1(1.1)                                  | 2(2.2)            | 3(3.3)                                  |              |
| Stage              |                                          |                                          |                   |                                          | 0.649        |
| Stage I            | 6(12.0)                                  | 2(4.0)                                  | 0(0)              | 0(0)                                    |              |
| Stage IIA          | 5(8.6)                                   | 0(0)                                    | 0(0)              | 0(0)                                    |              |
| Stage IIB          | 4(12.9)                                  | 0(0)                                    | 1(3.2)            | 2(6.5)                                  |              |
| Stage IIIA         | 3(12.0)                                  | 1(4.0)                                  | 1(4.0)            | 1(4.0)                                  |              |
| Stage IIIB         | 1(9.1)                                   | 0(0)                                    | 0(0)              | 0(0)                                    |              |
| Stage IIIIC        | 0(0)                                     | 1(5.9)                                  | 1(5.9)            | 0(0)                                    |              |
| Stage IV           | 5(7.5)                                   | 0(0)                                    | 2(3.0)            | 1(1.5)                                  |              |
| Side               |                                          |                                          |                   |                                          | 0.224        |
| Right              | 12(9.8)                                  | 0(0)                                    | 1(0.8)            | 2(1.6)                                  |              |
| Left               | 12(9.2)                                  | 4(3.1)                                  | 3(2.3)            | 2(1.5)                                  |              |
| Bilateral          | 0(0)                                     | 0(0)                                    | 1(12.5)           | 0(0)                                    |              |
| Age (years)        |                                          |                                          |                   |                                          | 0.032        |
| <55                | 18(11.5)                                 | 3(1.9)                                  | 0(0)              | 3(1.9)                                  |              |
| > 55               | 6(5.7)                                   | 3(1.0)                                  | 3(4.8)            | 1(1.0)                                  |              |
| Hypertension       |                                          |                                          |                   |                                          | 0.310        |
| With               | 3(6.1)                                   | 2(4.1)                                  | 2(4.1)            | 1(2.0)                                  |              |
| Without            | 21(9.9)                                  | 2(0.9)                                  | 3(1.4)            | 3(1.4)                                  |              |
| Diabetes           |                                          |                                          |                   |                                          | 0.782        |
| With               | 2(10.0)                                  | 0(0)                                    | 1(5.0)            | 0(0)                                    |              |
| Without            | 22(9.2)                                  | 4(1.7)                                  | 4(1.7)            | 4(1.7)                                  |              |
| Smoke              |                                          |                                          |                   |                                          | 0.940        |
| With               | 1(7.7)                                   | 0(0)                                    | 0(0)              | 0(0)                                    |              |
| Without            | 23(9.3)                                  | 4(1.6)                                  | 5(2.0)            | 4(1.6)                                  |              |
| Hyperlipidemia     |                                          |                                          |                   |                                          | 0.213        |
| With               | 0(0)                                     | 0(0)                                    | 1(12.5)           | 0(0)                                    |              |
| Without            | 24(9.5)                                  | 4(1.6)                                  | 4(1.6)            | 4(1.6)                                  |              |
| Radiotherapy       |                                          |                                          |                   |                                          | 0.821        |
| With               | 13(8.2)                                  | 2(1.3)                                  | 4(2.5)            | 3(1.9)                                  |              |
| Without            | 10(10.4)                                 | 2(2.1)                                  | 1(1.0)            | 1(1.0)                                  |              |

EF = ejection fraction; n = number; CHF = congestive heart failure; ICU = intensive care unit

* Taxane included docetaxel and paclitaxel

doi:10.1371/journal.pone.0151112.t002
aids and cessation of trastuzumab use. Angiotensin-converting-enzyme inhibitors (ACEIs), β-blockers, and diuretics were used to treat CHF (Table 3).

**Discussion**

Several clinical trials have demonstrated that trastuzumab significantly enhances therapeutic response and reduces the risk of recurrence for patients with either metastatic or early-stage HER2-overexpressing BC [13–15]. Patients in these studies either received a loading dose of 4 mg/kg intravenously, followed by a weekly infusion of 2 mg/kg, or were placed on a triweekly protocol with a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for 1 year in adjuvant therapy or a longer period in metastatic setting.

In Taiwan, one vial of trastuzumab contains 440 mg. According to the policies of our National Health Insurance Administration, some early-stage BC patients might need to pay for
trastuzumab out of pocket. Therefore, we decided to simplify the infusion protocol by decreasing the frequency of infusions in our patients. In our study, we have demonstrated that a monthly fixed-dose of 440 mg trastuzumab was effective in both adjuvant and metastatic settings. In our metastatic cohort, the median time to progression was 15.35 months versus 9.93 months for the fixed-dose versus the weighted-dose protocol (\( p = 0.23 \); Fig 1A). Since this is a retrospective study, the trastuzumab treatment may be the first or one of several lines of anti-cancer treatment in these patients. Treatment response was good compared with previous trials, which included both first-line and multiple prior lines of anti-cancer treatment in these patients. The median OS was also good in both groups, 53.16 months versus 39.06 months in the QM versus Q3W groups (\( p = 0.19 \); Fig 1B). In the adjuvant cohort, we found that fixed-dose protocol was feasible and effective for clinical practice; the medians of both PFS and OS were not reached.

HER signaling can modulate the myocardial response to chemotherapy-induced injury and may worsen anthracycline-related cardiotoxicity [17]. The North Central Cancer Treatment Group N9831 adjuvant breast cancer trial showed that the 3-year cumulative incidence of CHF was 2.8% to 3.3% [7]. The incidence of CHF requiring medication in our cohort was 3.4%. Six of these patients were in the Q3W group, and three were in the QM group. The incidence of

| Case | Age (years) | Stage | Group | CT | Trastuzumab interval | CV toxicity (grade) | Time to CV event (month) | EF % change (最低/最高) | Time to EF>50% (month) | Trastuzumab Re-use | Medication |
|------|------------|-------|-------|----|---------------------|--------------------|-------------------------|-------------------------|------------------------|------------------|------------|
| 1    | 64         | IIIC   | Adjuvant | A→T | Q3W     | 3                  | 8.98                    | 30/62                   | 9.0                    | No                | ACEI, diuretics, Ubiheart |
| 2    | 73         | IIB    | Adjuvant | CMF | QM      | 3                  | 1.38                    | 30/57                   | 7.0                    | No                | β-blocker, diuretics |
| 3    | 63         | IIIA   | Adjuvant | E→T | Q3W     | 3                  | 2.53                    | 20/35                   | NR                     | No                | ACEI        |
| 4    | 45         | IIB    | Adjuvant | A→T | Q3W     | 4                  | 9.44                    | 15/60                   | 14.0                   | No                | ACEI, β-blocker, diuretics, Ubiheart |
| 5    | 32         | IIIC   | Adjuvant | E→T | QM      | 2                  | 4.54                    | 50/67                   | 1.0                    | Yes               | No          |
| 6    | 59         | IIIA   | Adjuvant | A→T | Q3W     | 4                  | 2.63                    | 40/60                   | 7.0                    | No                | ACEI, β-blocker, diuretics, Ubiheart |
| 7    | 55         | IIIA   | Adjuvant | A→T | Q3W     | 2                  | 4.14                    | 20/64                   | 9.5                    | No                | ACEI, β-blocker, diuretics |
| 8    | 51         | IIB    | Adjuvant | A→T | Q3W     | 4                  | 0.39                    | 20/60                   | 20.0                   | No                | Ubiheart |
| 9    | 54         | I      | Adjuvant | T   | Q3W     | 2                  | 6.21                    | 50/66                   | 3.0                    | Yes               | No          |
| 10   | 41         | I      | Adjuvant | A   | QM      | 2                  | 2.89                    | 45/63                   | 3.0                    | No                | ACEI |
| 11   | 47         | IV     | Metastases | A | QM      | 4                  | 14.79                   | 30/45                   | NR                     | No                | β-blocker, diuretics, Ubiheart |
| 12   | 55         | IV     | Metastases | A→T | Q3W     | 3                  | 8.05                    | 29/45                   | NR                     | No                | β-blocker |
| 13   | 66         | IV     | Metastases | A | QM      | 3                  | 6.44                    | 15/25                   | NR                     | No                | ACEI, diuretics |

CT: chemotherapy, CV: cardiovascular, EF: ejection fraction, A→T: doxorubicin to taxane, E→T: epirubicin to taxane, T: taxane, A: doxorubicin, CMF: cyclophosphamide/methotrexate/fluorouracil, NR: no recovery, ACEI: angiotensin-converting-enzyme inhibitor, Ubiheart: ubidecarenone

doi:10.1371/journal.pone.0151112.t003
CHF in our trial was lower than that in some previous clinical trials (4.7%) [16]. However, very few researchers have ever analyzed the effect of dosage differences on cardiotoxicity. Belkacémi et al. [9] found that weekly infusions of trastuzumab lead to a higher rate of LVEF decrease. Combined with our data, we can postulate that increasing the trastuzumab dose while prolonging the interval between scheduled infusions will not increase the incidence of cardiac events.

Whether radiotherapy increases cardiac mortality is still controversial [18, 19]. In our metastatic and adjuvant cohorts, both radiotherapy and lesion side did not correlate with cardiac myopathy. Some have suggested that modern radiotherapy techniques markedly reduce cardiac risk, but long-term follow up is needed. Several studies have evaluated the correlation between trastuzumab-related CHF and possible CV risk factors, including age, hypertension, anthracycline-containing regimens, smoking, and diabetes [20]. In our study group, we found that patients aged less than 55 years might have a higher incidence of cardiac events (15.3% versus 12.5%, \( p = 0.032 \)). It is possible that a higher proportion of our younger patients received anthracycline-containing therapy, which may worsen cardiac toxicity (76.2% versus 65.5%, \( p = 0.021 \)). Russo et al. [21] found that patients with hypertension had a relatively higher incidence of trastuzumab-related CHF. They also found that onset of CHF predominantly occurred in the first 6 months of the treatment, which was similar to the findings from our group (median onset of cardiac events 4.54 months; Fig 2A). Therefore, we suggest that for higher-risk groups we should monitor cardiac function much more intensively during the first year of trastuzumab administration.

In our study, the trastuzumab discontinuation rate was 4.2%, compatible with the results of previous clinical studies (4.2% in the HERA trial to 17.0% in the N9831 trial). Most of our patients were treated with diuretics, ACEIs, β-blockers, and other drugs. Nine of 13 patients (69.2%) responded to these therapies with obvious symptomatic improvement and LVEF recovery to more than 50%. Two patients with initial asymptomatic grade II cardiotoxicity received a trastuzumab rechallenge and did not experience any episodes of heart failure or toxicity of more than grade I severity. In current clinical practice, trastuzumab rechallenge is generally recommended primarily in the metastatic setting or following careful evaluation of risks and benefits after LVEF returns to normal [20]. Ubidecarenone, also known as coenzyme Q\(_{10}\) (CoQ\(_{10}\)), is a powerful antioxidant, and reduced concentrations of myocardial tissue CoQ\(_{10}\) is associated with the severity of CHF. Mortensen et al. reported that concurrently administering CoQ\(_{10}\) and standard therapy for CHF patients could improve symptoms and reduce CV mortality, but it could not significantly improve LVEF [22]. There were five patients who received CoQ\(_{10}\) treatment in our analysis. Four had severe grade IV events and one experienced grade III heart failure. However, only one patient, case #11, received long-term CoQ\(_{10}\) treatment due to the uncontrolled CHF. The rest of the patients stopped taking CoQ\(_{10}\) when LVEF recovered or the CHF was well controlled. Currently, there is limited data about the role of CoQ\(_{10}\) in the treatment of trastuzumab-induced cardiotoxicity. More prospective studies are necessary.

Currently, increasing health care costs must be considered, and cost-effectiveness analyses are used frequently to assist government payers to make decisions about whether the therapy is worthwhile. Trastuzumab is a relatively expensive drug. Several cost-effectiveness analyses support the use of trastuzumab in both early and metastatic BC patients [23, 24]. Ward et al. [25] suggested that the dosing protocol used in the FinHer study [14], with its shortened regimen, might be equally effective and be more convenient for patients. Although there were no head-to-head comparisons of the 9 week and 12 month treatments, the protocol used in the FinHer study proved to be effective [26]. In Taiwan, we only have one dosage of trastuzumab available, with 440 mg per vial. The 150 mg vials that are available elsewhere are not sold here. In the Q3W group, averagely 18.2% of trastuzumab dispensed for each cycle in the adjuvant setting was discarded, as well as 23.8% was wasted in the metastatic setting according to our analysis.
Therefore, using a fixed-dose of 440 mg of trastuzumab every month is not only very convenient to patients and pharmacists, but it can also reduce waste of a costly drug. In the pharmacoeconomic point of view, for example, a 60-kilogram woman receives adjuvant trastuzumab therapy with 360 mg dosage every three weeks for totally 18 cycles. The cost is around NT$60,000 for each cycle, including the waste. Using 440 mg fixed dosage every month, the cost for each cycle is the same, but the total expense will be 33% off because only 12 cycles are needed. In patients with metastatic breast cancer, the median treatment courses in our cohort for both groups are 15 cycles, therefore the cost is the same, but the treatment period is longer in QM group.

There are several limitations of our study owing to its retrospective design, including heterogeneity of patients and disease status, lack of pharmacokinetic information, different chemotherapeutic protocols and existence of selection bias yielded by patients and physicians. It raises a concern that these two dosing schedules cannot be compared equally and properly. Consequently, we only demonstrate the feasibility and effectiveness of the fixed-dose monthly protocol in this study. Further large randomized prospective are warranted to confirm the relative merits of these two dosing schedules. The initial trastuzumab pharmacokinetic studies suggested that the half-life was 6–8 days. However, plasma levels with tri-weekly dosage are similar to those with conventional weekly dosage, which can prove that chronic administration prolongs the elimination half-life of trastuzumab [27]. Therefore, we believe that a fixed-dose monthly schedule should be feasible to maintain the effective serum trastuzumab level. Besides, biomarkers were not evaluated in our study. Some studies reported that elevated high-sensitivity C-reactive protein, cardiac troponin I, and troponin T appeared to predict trastuzumab-induced cardiotoxicity [20, 28, 29]. However, regular follow-up of the biomarkers is not suggested because conflicting results of these biomarkers existed among the previous trials.

In conclusion, fixed-dose regimens of trastuzumab are simple and feasible for daily clinical practice. CV risk is not higher than in previous clinical trials. The regimen is also economically feasible. Larger-scale studies with longer-term follow up are needed to confirm our results.

Acknowledgments

The authors thank Dr. Anthony Janckila for critical review of the manuscript. This study was supported by a grant issued from the Tri-Service General Hospital (TSGH-C105-166).

Author Contributions

Conceived and designed the experiments: YYW TCH TYC. Performed the experiments: YYW TCH TNT. Analyzed the data: YYW TCH TRC. Contributed reagents/materials/analysis tools: JHC MSD PYC CLH RHY YCC TYC. Wrote the paper: YYW TCH.

References

1. Gschwind A, Fischer OM, Ulrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature reviews Cancer. 2004; 4(5):361–70. Epub 2004/05/04. doi:10.1038/nrc1360 PMID: 15122207.

2. Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(28):4423–30. Epub 2007/10/02. doi: 10.1200/JCO.2007.11.0973 PMID: 17906205.

3. Vogel CL, Cobleigh MA, Tripathy D, Guthel JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20(3):719–26. Epub 2002/02/01. PMID: 11821453.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine. 2001; 344(11):783–92. Epub 2001/03/15. doi: 10.1056/NEJM200103153441101 PMID: 11248153.

5. Puputti M, Sihto H, Isola J, Butzow R, Joensuu H, Nupponen NN. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer genetics and cytogenetics. 2006; 167(1):32–8. Epub 2006/05/10. doi: 10.1016/j.cancergenet.2004.09.023 PMID: 16682283.

6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine. 2005; 353(16):1673–84. Epub 2005/10/21. doi: 10.1056/NEJMoa052122 PMID: 16236738.

7. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 28(8):1231–8. Epub 2008/02/06. doi: 10.1200/JCO.2007.13.5467 PMID: 18250349; PubMed Central PMCID: PMC4048960.

8. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(25):3859–65. Epub 2007/07/25. doi: 10.1200/JCO.2006.09.1611 PMID: 17646669.

9. Belkacemi Y, Gilgorov J, Ozsahin M, Marsigilia H, De Lafontan B, Laharie-Mineur H, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2008; 19(6):1110–6. doi: 10.1093/annonc/mdn029 PMID: 18344537.

10. Ewer MS, Vooletcit MH, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(31):7820–6. Epub 2005/11/01. doi: 10.1200/JCO.2005.13.300 PMID: 16258084.

11. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369(9555):29–36. Epub 2007/01/09. doi: 10.1016/S0140-6736(07)6028-2 PMID: 17208639.

12. Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia—monitoring the effect of an expensive medicine access program. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(24):3688–93. Epub 2007/08/21. doi: 10.1200/JCO.2007.11.2516 PMID: 17704417.

13. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(9):2639–48. PMID: 10561337.

14. Joensuu H, Kellockumpe-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New Engl J Med. 2006; 354(8):809–20. doi: 10.1056/NEJmoa053028 PMID: WOS:000235456200005.

15. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. The New England journal of medicine. 2011; 365(14):1273–83. doi: 10.1056/NEJMoa0910383 PMID: 21991949; PubMed Central PMCID: PMC3268553.

16. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, et al. Trastuzumab-containing regimens for metastatic breast cancer. The Cochrane database of systematic reviews. 2014; 6:CD006242. Epub 2014/06/13. doi: 10.1002/14651858.CD006242.pub2 PMID: 24919460.

17. Sawyer DB, Zupping C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002; 105(13):1551–6. Epub 2002/04/03. PMID: 11927521.

18. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. Journal of the National Cancer Institute. 2005; 97(8):419–24. Epub 2005/03/17. doi: 10.1093/jnci/dij087 PMID: 15770005; PubMed Central PMCID: PMC1853253.

19. Patt DA, Goodwin JS, Kuo YF, Freeman JL, Zhang DD, Buchholz TA, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(30):7475–82. Epub 2005/09/15. doi: 10.1200/JCO.2005.13.755 PMID: 16157933.
20. Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Therapeutic advances in drug safety. 2014; 5(4):154–66. doi: 10.1177/2042098614529603 PMID: 25083270; PubMed Central PMCID: PMC4110857.

21. Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, et al. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. Journal of cardiovascular medicine. 2014; 15(2):141–6. doi: 10.2459/JCM.0b013e328365af65 PMID: 24534802.

22. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart failure. 2014; 2(6):641–9. doi: 10.1016/j.jchf.2014.06.008 PMID: 25282031.

23. Perez-Ellis C, Goncalves A, Jacquemier J, Marty M, Girre V, Roche H, et al. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer. American journal of clinical oncology. 2009; 32(5):492–8. Epub 2009/06/03. doi: 10.1097/COC.0b013e3181931277 PMID: 19487912.

24. Chan AL, Leung HW, Lu CL, Lin SJ. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. The Annals of pharmacotherapy. 2009; 43(2):296–303. Epub 2009/02/06. doi: 10.1345/aph.1L504 PMID: 19193576.

25. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health technology assessment. 2009; 13 Suppl 1:1–6. doi: 10.3310/hta13suppl1/01 PMID: 19567207.

26. Purmonen TT, Pankalainen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta oncologica. 2011; 50(3):344–52. Epub 2011/02/09. doi: 10.3109/0284186X.2011.553841 PMID: 21299447.

27. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocrine-related cancer. 2002; 9(2):75–85. PMID: 12121832.

28. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(25):3910–6. doi: 10.1200/JCO.2009.27.3615 PMID: 20679614.

29. Katsurada K, Ichida M, Sakurai M, Takehana M, Hozumi Y, Kario K. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy. Springer-Plus. 2014; 3:620. doi: 10.1186/2193-1801-3-620 PMID: 25392790; PubMed Central PMCID: PMC4216824.